Dernières nouvelles pour Zoetis (NYSE:ZTS) Stock

Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Zoetis Inc

BMO ST TRM US TRY BD INX USD UNT ETF

Ztest Electronics Inc

The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of <a href="https://www.benzinga.com/topic/election-day">Election Day on Tuesday</a>. 
Vice President Kamala Harris holds a 1-point lead over ex-President Donald Trump, according to the New York Times national polling average; she has a 4-point lead among likely voters nationally, <a href="https://maristpoll.marist.edu/polls/u-s-presidential-contest-november-2024/">according to the latest PBS News/NPR/Marist poll</a>.
Betting markets, as tracked by the CFTC-regulated Kalshi, favor a Trump win at a 53% chance, <a href="https://www.benzinga.com/general/politics/24/11/41702729/harris-surges-in-prediction-markets-nabs-kalshi-lead-with-just-three-days-to-go">but with diminishing odds</a> compared to previous weeks. Also, the betting odds are susceptible to wild swings from so-called "whale" bettors, including one individual on Polymarket <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41463756/polymarket-to-review-user-base-in-light-of-whales-betting-millions-on-trump-election-win" target="_blank" rel="noreferrer noopener">who spent as much as</a> $43 million on a Trump victory.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41717129/polymarkets-all-time-leading-trader-bets-over-500-000-on-kamala-harris-slams-nate-silver-f">Polymarket&#8217;s All-Time Leading Trader Bets Over $500,000 On Kamala Harris, Slams Nate Silver For Including &#8216;Fake Poll&#8217; Data In Model</a>
&#8220;Neither candidate holds a meaningful edge in enough states to win 270 electoral votes. In the history of modern polling, there's never been a race where the final polls showed such a close contest,&#8221; said Nate Cohn, chief political analyst for the New York Times. 
The S&amp;P 500 slipped 0.2%, while the Dow dropped 0.6%, hitting its lowest intraday level since mid-September. In contrast, small-cap stocks in the Russell 2000 outperformed, rising 1%. The Nasdaq 100 also retreated, dipping below the 20,000 mark.
Treasury yields fell by nearly 10 basis points as investors scaled back positions linked to Trump&#8217;s inflationary policies, such as high tariffs and more expansionary fiscal measures. The dollar also weakened, down 0.5%.
The increasing likelihood of a Harris victory gave a boost to solar and renewable energy stocks, with the Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) climbing 3.6%. 
Oil and gas stocks also gained, as crude prices surged 3% after OPEC+ postponed an anticipated production hike. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) jumped 3%, marking its largest single-day gain since late June.
Gold held steady at $2,740, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell over 1%, dropping below $68,000.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,230.95</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,715.31</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,978.22</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,807.92</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.1% to $570.22.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.5% to $418.44.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.2% to $486.77.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $221.27.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, rising 1.7%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.5%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), down 3.9%, </li>
<li>Constellation Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NYSE">CEG</a>), down 10.5%, </li>
<li>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), down 1.8%, </li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), down 0.4%, </li>
<li>Public Service Enterprise Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>), down 5.9%, </li>
<li>TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), down 5.5%. </li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>), up 3.7%, </li>
<li>YUM China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>), up 7.9%, </li>
<li>Loews Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>), down 4.8%, </li>
</ul>
Stocks slated to report earnings after the close are Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) and Astera Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41702887/harris-takes-lead-in-red-state-iowa-in-shock-poll">Harris Takes Lead In Red State Iowa In Shock Poll</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Politics

Economics

Tech

ETFs

$BTC

ALAB

SPDR Dow Jones Industrial Average ETF Trust

FANG

HOLX

ILMN

NXPI

PLTR

VRTX

Select Sector SPDR-Consumer Discretionary

YUMC

Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?

On Monday,&nbsp;Zoetis Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) third-quarter 2024 adjusted EPS increased 16% year over year to $1.58, beating the <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">consensus of $1.46</a>.
The animal health firm reported sales of $2.39 billion, up 11%, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41709533/zoetis-announces-third-quarter-2024-results" rel="noreferrer noopener">consensus of $2.29 billion</a>.
On an operational&nbsp;basis, revenue for the third quarter of 2024 increased 14% compared with the third quarter of 2023.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40959456/elancos-dermatology-treatment-secures-fda-approval-for-itchy-dogs-analyst-highlight" rel="noreferrer noopener">Elanco&#8217;s Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy</a>
&#8220;Building on the strong momentum from the first half of the year, we are proud to have delivered another excellent quarter, fueled by our diverse, durable, and science-driven portfolio and our customer obsession that underscore our market leadership,&#8221; said Kristin Peck, Chief Executive Officer of Zoetis.
&#8220;We achieved 15% revenue growth in the U.S. and 13% operational revenue growth internationally, with both our companion animal and livestock portfolios seeing impressive global operational growth, 15% and 11%, respectively.&#8221;
Guidance: Zoetis raised its 2024 revenue guidance to $9.2 billion—$9.3 billion, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40197088/animal-health-firm-zoetis-clocks-strong-q2-earnings-companion-animal-operations-boo" rel="noreferrer noopener">compared to prior guidance</a> of $9.1 billion—$9.25 billion and consensus of $9.194 billion. This is equivalent to an operational growth of 10% %- 11%.
Zoetis raised the 2024 adjusted EPS to $5.86-$5.92 versus prior guidance of $5.78-$5.88 and consensus of $5.82.
The company sees an adjusted net income of $2.67 billion-$2.695 billion, reflecting operational growth of 13.5%-14.5, with a reported net income of net income between $2.435 billion-$2.450 billion.
William Blair writes, &#8220;We view companion animal as the main driver of sentiment for shares and were encouraged to see 15% global growth in the segment despite concerns about competition and end-market noise.&#8221;
The analyst reaffirms an Outperform rating based on Zoetis&#8217;s third-quarter results, which initially appear to support the expectation for double-digit EPS growth in 2025.
Guidance and insights for 2025 provided during 2024 earnings will be the main factor driving valuation growth, William Blair analyst writes.
Price Action: ZTS stock is down 3.88% at $174.86 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" target="_blank" rel="noreferrer noopener">Viking Therapeutics&#8217; Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety</a></li>
</ul>
Photo by huoadg5888 via <a href="https://pixabay.com/photos/pets-cat-dog-animals-mammals-3715733/">Pixabay</a>

Analyst Color

Earnings

News

Guidance

Health Care

Analyst Ratings

Movers

General

Zoetis Q3 Earnings Beat, Companion Animal Segment Growth Gives Confidence Into 2025: Analyst

Zoetis shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance above estimates.

Zoetis Expects 2024 Adjusted EPS Of $5.86-$5.92 Versus Prior Guidance Of $5.78-$5.88 And Consensus Of $5.82

Zoetis is raising its full year 2024 guidance for revenue and adjusted EPS due to the company's strong first three quarters and the underlying strength in companion animal.
<ul>
<li>Revenue between $9.200 billion to $9.300 billion (operational growth of 10% to 11%)</li>
<li>Reported net income between $2.435 billion to $2.450 billion</li>
<li>Adjusted net income between $2.670 billion to $2.695 billion (operational growth of 13.5% to 14.5%)</li>
<li>Reported diluted EPS of $5.33 to $5.39</li>
<li>Adjusted diluted EPS between $5.86 to $5.92</li>
</ul>

Zoetis Raises 2024 Revenue Guidance Of $9.2B-$9.3B Versus Prior Guidance Of $9.1B-$9.25B And Consensus Of $9.194B

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.46 by 8.22 percent. The company reported quarterly sales of $2.39 billion which beat the analyst consensus estimate of $2.29 billion by 4.36 percent. This is a 11.02 percent increase over sales of $2.15 billion the same period last year.

Zoetis Q3 2024 Adj EPS $1.58 Beats $1.46 Estimate, Sales $2.39B Beat $2.29B Estimate

Kevin O'Leary, better known as Mr. Wonderful from Shark Tank, knows a thing or two about making bets that pay off — especially the crazy ones. In a <a href="https://www.youtube.com/watch?app=desktop&amp;v=8H1GauGOO3k">discussion</a> with Chris Wallace, O'Leary opened up about the unpredictable world of venture investing.
Don't Miss:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
He explained how some of his most bizarre investments, like a company offering genetic testing for cats, turned into massive wins that covered a bunch of other losses. The truth? Venture investing is random, and a lot of it comes down to luck.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I get this one shoved in my face all the time. I'm the only Shark that believed in him! The truth is, venture investing is random. There's a lot of luck involved and you need diversification. <a href="https://t.co/06LyCCK2IJ">pic.twitter.com/06LyCCK2IJ</a>
&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1850917130398470260?ref_src=twsrc%5Etfw">October 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Back in 2019, O&#8217;Leary made a seemingly wild bet on Basepaws, <a href="https://www.benzinga.com/startups/24/08/40557261/the-stupid-idea-that-made-kevin-oleary-a-massive-20x-return-it-was-such-a-crazy-pitch-i-bought-it-an">a startup that provides DNA tests for cats</a>. At first glance, it seemed like a quirky, maybe even questionable idea. But Mr. Wonderful went for it anyway. He invested alongside fellow shark Robert Herjavec, each putting in $125,000 for a 5% stake.&nbsp;
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a>
Fast forward a few years, and Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), a giant in the animal health industry, scooped up Basepaws for well over $50 million. That acquisition meant O'Leary&#8217;s initial investment potentially turned into a 90x return — not bad for something that sounded like a pet gimmick at the start.
"Venture investing is random," O'Leary admitted. "There's a lot of luck in it." For him, diversification is key. O&#8217;Leary explained that, out of the 10-15 deals he makes each year, only a few will end up being big wins, but they're the ones that make all the difference. And often, the winners are the ideas that seem the most unpredictable, like cat DNA tests or a meal-kit service like Plated, which was sold to Albertsons for about $300 million.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
A notable deal that got away from O&#8217;Leary was Ring, the smart doorbell company. He famously passed on Ring when it was pitched on Shark Tank, and it was later sold to Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) for $1 billion. As he told Wallace, &#8220;Thank you for bringing it up Chris. You&#8217;ve ruined my day. I get this one shoved in my face all the time.&#8221;
In a recent <a href="https://www.youtube.com/watch?v=zFCfU9cBIRA">podcast</a>, O&#8217;Leary revealed a fascinating stat — 70% of his returns come <a href="https://www.benzinga.com/startups/24/10/41254217/if-they-say-ive-got-three-kids-i-dont-care-says-kevin-oleary-claims-70-of-his-returns-come-from-wome">from companies led by women</a>. He's found that women entrepreneurs tend to be strong at managing risk, making deliberate choices that help their businesses stay steady even when things get tough. "If you want something done, give it to a busy mother," O&#8217;Leary said, highlighting how balancing multiple responsibilities can make someone a great leader.
To O&#8217;Leary, venture investing is more about taking risks, spreading bets, and understanding that the most unusual concepts can occasionally lead to the greatest returns.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

AMZN

'Venture Investing Is Random,' Says Kevin O'Leary. The Craziest Bets, Like Cat DNA Tests, Often Cover All The Losses

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 6.56% on an annualized basis producing an average annual return of 18.21%. Currently, Zoetis has a market capitalization of $86.12 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $5,430.67 today based on a price of $190.08 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728932418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Zoetis 10 Years Ago Would Be Worth Today

In the preceding three months, 7 analysts have released ratings for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $213.57, a high estimate of $230.00, and a low estimate of $200.00. Marking an increase of 5.04%, the current average surpasses the previous average price target of $203.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1728658890_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Zoetis is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$220.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zoetis. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zoetis compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Zoetis's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Zoetis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zoetis analyst ratings.</a>
<h2>All You Need to Know About Zoetis</h2>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Zoetis's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Zoetis displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.3%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zoetis's net margin is impressive, surpassing industry averages. With a net margin of 26.43%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Zoetis's ROE stands out, surpassing industry averages. With an impressive ROE of 12.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.38%, the company showcases effective utilization of assets.
Debt Management: Zoetis's debt-to-equity ratio is below the industry average at 1.36, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 7 Analyst Recommendations For Zoetis

JP Morgan analyst Chris Schott maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and raises the price target from $225 to $230.

Price Target

JP Morgan Maintains Overweight on Zoetis, Raises Price Target to $230

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$20.00</td>
<td>$41.4K</td>
<td>389</td>
<td>5.5K</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$260.00</td>
<td>$25.2K</td>
<td>849</td>
<td>1.4K</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$190.00</td>
<td>$27.6K</td>
<td>4.0K</td>
<td>718</td>
</tr>
<tr>
<td>NVCR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$13.00</td>
<td>$27.6K</td>
<td>110</td>
<td>691</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$490.00</td>
<td>$30.8K</td>
<td>250</td>
<td>161</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$39.1K</td>
<td>6.6K</td>
<td>113</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$70.7K</td>
<td>2.6K</td>
<td>92</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$32.2K</td>
<td>1.8K</td>
<td>66</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$100.00</td>
<td>$26.7K</td>
<td>420</td>
<td>59</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$600.00</td>
<td>$40.6K</td>
<td>464</td>
<td>51</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 4 day(s) on October 11, 2024. Parties traded 901 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $41.4K, with a price of $46.0 per contract. There were 389 open contracts at this strike prior to today, and today 5520 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on October 11, 2024. Parties traded 120 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $25.2K, with a price of $210.0 per contract. There were 849 open contracts at this strike prior to today, and today 1476 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a put option sweep that happens to be bullish, expiring in 11 day(s) on October 18, 2024. This event was a transfer of 60 contract(s) at a $190.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $460.0 per contract. There were 4070 open contracts at this strike prior to today, and today 718 contract(s) were bought and sold. 
• For NVCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>), we notice a put option sweep that happens to be bearish, expiring in 11 day(s) on October 18, 2024. This event was a transfer of 690 contract(s) at a $13.00 strike. This particular put needed to be split into 63 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $40.0 per contract. There were 110 open contracts at this strike prior to today, and today 691 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bullish, expiring in 39 day(s) on November 15, 2024. This event was a transfer of 16 contract(s) at a $490.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $30.8K, with a price of $1930.0 per contract. There were 250 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 466 day(s) on January 16, 2026. Parties traded 44 contract(s) at a $50.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $890.0 per contract. There were 6607 open contracts at this strike prior to today, and today 113 contract(s) were bought and sold. 
• For SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we notice a put option trade that happens to be bearish, expiring in 102 day(s) on January 17, 2025. This event was a transfer of 68 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $70.7K, with a price of $1040.0 per contract. There were 2682 open contracts at this strike prior to today, and today 92 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bearish sentiment. It expires in 466 day(s) on January 16, 2026. Parties traded 43 contract(s) at a $45.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $750.0 per contract. There were 1834 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a put option sweep with bullish sentiment. It expires in 347 day(s) on September 19, 2025. Parties traded 50 contract(s) at a $100.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.7K, with a price of $535.0 per contract. There were 420 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bullish, expiring in 466 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $40.6K, with a price of $2030.0 per contract. There were 464 open contracts at this strike prior to today, and today 51 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

NVCR

SAVA

10 Health Care Stocks Whale Activity In Today's Session

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 6.65% on an annualized basis producing an average annual return of 18.1%. Currently, Zoetis has a market capitalization of $88.26 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $5,144.18 today based on a price of $194.81 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727712024_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Zoetis 10 Years Ago Would Be Worth This Much Today

Zoetis and Danone recently announced a joint business development plan to drive sustainable practices on today's dairy farms through the power of genetics for healthier cows. Combining Danone's commitment to environmental stewardship with Zoetis' expertise in animal genetics, the partnership aims to innovate the dairy industry's approach to breeding for sustainability.
The plan between the two companies is intended to enable <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.danone.com%2F&amp;esheet=54127168&amp;newsitemid=20240925718835&amp;lan=en-US&amp;anchor=Danone&amp;index=1&amp;md5=43afadd725925a2b222afc2c70be74b9">Danone</a> to leverage Zoetis' cutting-edge genetic technologies globally. The focus is on integrating sustainable practices into dairy genetics and selection, emphasizing animal well-being, reducing environmental impact, and promoting long-term resilience in dairy farming.

Zoetis And Danone Recently Announced A Joint Business Development Plan To Drive Sustainable Practices On Today's Dairy Farms Through The Power Of Genetics For Healthier Cows

On Thursday, the FDA approved Elanco Animal Health Incorporated&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) Zenrelia, a once-daily oral JAK inhibitor for the control of pruritus (itching) associated with allergic dermatitis and atopic dermatitis in dogs at least <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40946416/elanco-announces-fda-approval-and-launch-of-zenrelia-ilunocitinib-tablets-offering-an-effective-sa" rel="noreferrer noopener">12 months of age</a>.
Approximately 17 million dogs suffer from allergic skin disease, including atopic dermatitis, food allergies, or flea sensitivity.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39530951/elanco-animal-health-shares-sink-on-unexpected-label-update-for-canine-dermatology-" rel="noreferrer noopener">Elanco Animal Health Shares Sink On Unexpected Label Update For Canine Dermatology Drug</a>.
Elanco conducted a head-to-head noninferiority study comparing the efficacy and safety of Zenrelia and Apoquel for submission in the European Union.
A study of 338 client-owned dogs with confirmed atopic dermatitis was conducted.
The study shows one daily dose of Zenrelia is at least as effective as the market incumbent JAK inhibitor at the primary endpoint on Day 28.
<ul>
<li>Zenrelia provided consistently greater relief from itch and skin lesions over time, with once-daily dosing from the start, while rebound itch was observed in Zoetis Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) Apoquel (oclacitinib)-treated dogs after dosing decreased to once daily after Day 14.</li>
<li>77% of Zenrelia-treated dogs achieved clinical remission of itch, compared to 53% of Apoquel-treated dogs.</li>
</ul>
William Blair highlights that Zenrelia&#8217;s label includes a warning advising discontinuation 28 days to 3 months before any vaccination. This raises concerns about whether veterinarians will readily adopt the new skin product, given the extra precautions needed, especially considering some dogs receive vaccines as frequently as once a year.
In reviewing the clinical data, it was noted that the placebo effect in Zenrelia&#8217;s FDA study was significantly higher than in Apoquel&#8217;s, suggesting that Apoquel&#8217;s actual impact on atopic dermatitis may be more robust than Zenrelia&#8217;s.
This raises doubts about Zenrelia&#8217;s true efficacy in comparison. Additionally, William points out that adverse events, such as diarrhea and vomiting, occurred at twice the rate in Zenrelia&#8217;s FDA study than in Apoquel&#8217;s.
The analyst notes that investor expectations for Zenrelia over the next two years are already elevated. However, due to lingering uncertainties, William prefers to wait for concrete execution before assessing if it can sustainably impact the P&amp;L statement. The analyst maintained the <a href="https://www.benzinga.com/quote/ELAN/analyst-ratings" target="_blank" rel="noreferrer noopener">Market Perform rating.</a>
Price Action: ELAN stock traded lower by 4.18% at $14.44 at the last check Friday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40946183/disney-strikes-first-look-deal-with-spider-man-director-jon-watts-report" target="_blank" rel="noreferrer noopener">Disney Strikes First-Look Deal With Spider-Man Director Jon Watts: Report</a>.</li>
</ul>

Reiteration

ELAN

Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy

Corcept Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cort#NASDAQ">CORT</a>) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock&#39;s 15.7% gain over the past four weeks.
The company&#39;s sole marketed drug, Korlym, approved for treating Cushing&#39;s syndrome, is witnessing strong demand and driving growth. Also, a new drug application for the lead candidate, relacorilant, to treat Cushing&#39;s syndrome is expected to be filed in the fourth quarter of 2024. The ongoing progress with Korlym and relacorilant could be the reason for the share price rally.
This drug developer is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -7.1%. Revenues are expected to be $171.04 million, up 38.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Corcept, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock&#39;s price usually doesn&#39;t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CORT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold).
Corcept is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Zoetis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zts#NYSE">ZTS</a>), finished the last trading session 0.4% higher at $196.48. ZTS has returned 6.6% over the past month.
For Zoetis, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.46. This represents a change of +7.4% from what the company reported a year ago. Zoetis currently has a Zacks Rank of #2 (Buy).
<a href="https://www.zacks.com/stock/news/2338319/corcept-cort-moves-6-5-higher-will-this-strength-last?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_5%-2338319">To read this article on Zacks.com click here.</a>

Markets

CORT

Corcept Moves 6.5% Higher: Will This Strength Last?

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised the price target for Aspen Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>) from  $200 to $217. Piper Sandler analyst Clarke Jeffries maintained a Neutral rating. Aspen Technology shares gained 3.3% to close at $233.54 on Tuesday. <a href="https://www.benzinga.com/quote/AZPN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital raised the price target for NMI Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMIH#NASDAQ">NMIH</a>) from $40 to $48. RBC Capital analyst Scott Heleniak upgraded the stock from Sector Perform to Outperform. NMI Holdings shares fell 1.4% to close at $41.15 on Tuesday. <a href="https://www.benzinga.com/quote/NMIH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. lifted Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) price target from $60 to $80. HC Wainwright &amp; Co. analyst Patrick Trucchio maintained a Buy rating. Longboard Pharmaceuticals shares fell 10.3% to close at $27.58 on Tuesday. S<a href="https://www.benzinga.com/quote/LBPH/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>Benchmark increased Belden Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDC#NYSE">BDC</a>) price target from $115 to $120. Benchmark analyst Reuben Garner maintained a Buy rating. Belden shares gained 2.9% to close at $106.29 on Tuesday. <a href="https://www.benzinga.com/quote/BDC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities boosted the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $112 to $118. B of A Securities analyst Sara Senatore maintained a Buy rating. Starbucks rose 0.1% to close at $96.44 on Tuesday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut Workday, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) price target from $350 to $300. Needham analyst Scott Berg maintained a Buy rating. Workday shares fell 0.4% to close at $248.12 on Tuesday. <a href="https://www.benzinga.com/quote/WDAY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) price target from $222 to $225. Baird analyst David Manthey maintained an Outperform rating. Ferguson Enterprises shares gained 5% to close at $207.06 on Tuesday. <a href="https://www.benzinga.com/quote/FERG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) from $347 to $345. B of A Securities analyst Ken Hoexter maintained a Buy rating. FedEx shares rose 1.6% to close at $297.34 on Tuesday. <a href="https://www.benzinga.com/quote/FDX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs raised The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) price target from $262 to $280. Goldman Sachs analyst Alex Scott maintained a Buy rating. Progressive shares rose 0.2% to close at $256.91 on Tuesday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) price target from $200 to $210. Stifel analyst Jonathan Block maintained a Buy rating. Zoetis shares rose 0.8% to close at $195.71 on Tuesday. <a href="https://www.benzinga.com/quote/ZTS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SBUX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="526" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141-1024x526.png" alt="" class="wp-image-553956" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141-1024x526.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141-768x394.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/18090157/image-141.png 1321w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/09/40898216/cramer-hewlett-packard-is-a-very-inexpensive-stock-likes-this-big-tech-stock">Cramer: Hewlett Packard Is A &#8216;Very Inexpensive&#8217; Stock, Likes This Big Tech Stock</a></li>
</ul>

Pre-Market Outlook

AZPN

FERG

LBPH

NMIH

SBUX

WDAY

Starbucks To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts' ratings for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $210.83, a high estimate of $225.00, and a low estimate of $200.00. This upward trend is evident, with the current average reflecting a 5.94% increase from the previous average price target of $199.00.
<img src="https://www.benzinga.com/files/images/story/2024/1726664459_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Zoetis's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$220.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Zoetis. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Zoetis compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Zoetis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Zoetis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZTS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zoetis analyst ratings.</a>
<h2>All You Need to Know About Zoetis</h2>
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
<h3>Understanding the Numbers: Zoetis's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Zoetis's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 8.3%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zoetis's net margin excels beyond industry benchmarks, reaching 26.43%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Zoetis's ROE stands out, surpassing industry averages. With an impressive ROE of 12.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Zoetis's ROA stands out, surpassing industry averages. With an impressive ROA of 4.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Zoetis's debt-to-equity ratio is below the industry average. With a ratio of 1.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Zoetis Stands With Analysts

Stifel analyst Jonathan Block maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Buy and raises the price target from $200 to $210.

Stifel Maintains Buy on Zoetis, Raises Price Target to $210

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 7.14% on an annualized basis producing an average annual return of 17.81%. Currently, Zoetis has a market capitalization of $83.85 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $5,160.31 today based on a price of $185.07 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725544824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 10 Years

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) reported a &#8220;<a href="https://www.benzinga.com/news/earnings/24/08/40482203/target-q2-earnings-revenue-and-profit-beat-digital-sales-boost-annual-profit-outlook-hiked">very, very good&#8221; quarter</a>. 
&#8220;It does yield 3%, which is actually quite good,&#8221; he added.
On Aug. 21, Target posted stellar second-quarter results outperformed earnings and sales expectations and prompted an optimistic boost to its full-year profit outlook. 
Quarterly adjusted earnings per share totaled $2.57 (+40%), beating the street view of $2.20. Target reported sales of $25.45 billion (+2.7%), exceeding the analyst consensus of $25.229 billion.
See Also: <a href="https://www.benzinga.com/news/earnings/24/03/37413962/how-to-earn-500-a-month-from-target-stock-ahead-of-q4-print">How To Earn $500 A Month From Target Stock Ahead Of Q4 Print</a>
Cramer also likes Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>).
On Aug. 6, Zoetis reported better-than-expected second-quarter financial results and raised its <a href="https://www.benzinga.com/quote/ZTS/analyst-ratings">2024 guidance above estimates</a>. The animal health company reported second-quarter revenue of $2.36 billion, up 8% year-over-year on reported and 11% on an operational basis, beating the consensus of $2.31 billion.
When asked about PROCEPT BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>), he said, &#8220;It's been a rocket, but I think if you're going to be in robotics, you have to be in ISRG.&#8221;
On Sept. 3, Truist Securities analyst Richard Newitter maintained PROCEPT BioRobotics with a Buy and raised the price target from $74 to $95.
&#8220;I've liked Con Ed for, I don't know, maybe 70 points,&#8221; Cramer said when asked about Consolidated Edison, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>). &#8220;As long as it's around, above three, I think the stock can still project itself even higher.&#8221;
On Aug. 1, Consolidated Edison reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 57 cents per share. The company reported quarterly sales of $3.22 billion which beat the analyst consensus estimate of $3.18 billion.
Price Action:
<ul>
<li>PROCEPT BioRobotics shares fell 5% to settle at $75.06 on Tuesday.</li>
<li>Zoetis shares gained 0.04% to close at $183.57.</li>
<li>Target shares fell 1.2% to close at $151.80 during Tuesday's session.</li>
<li>Consolidated Edison shares rose 1.7% to settle at $103.28 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40700996/dow-tumbles-over-600-points-nasdaq-dips-3-amid-plunge-in-nvidia-fear-index-remains-in-greed-zone">Dow Tumbles Over 600 Points, Nasdaq Dips 3% Amid Plunge In Nvidia: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

PRCT

Jim Cramer Says This Retailer Yields 3%: 'Which Is Quite Good'

Barclays analyst Balaji Prasad maintained a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $242.00. The company's sha...

Barclays Sticks to Their Buy Rating for Zoetis (ZTS)

Zoetis beats Q3 top and bottom line estimates, raises FY revenue guidance

Reports Q3 revenue $2.39B, consensus $2.29B. "Building on the strong momentum from the first half of the year, we are proud to have delivered anoth...

Zoetis reports Q3 adjusted EPS $1.58, consensus $1.45

Consensus $5.82. Raises FY24 revenue view to $9.2B-$9.3B from $9.1B-$9.25B, consensus $9.19B. The company said, "Zoetis (ZTS) is raising its full y...

Zoetis raises FY24 adjusted EPS view to $5.86-$5.92 from $5.78-$5.88

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – Air Transport Services&nbsp;(ATSG) up 23% after entering...

Morning Movers: Air Transport Services jumps following $3.1B take-private deal

Zoetis Inc. 2024 Q3 - Results - Earnings Call Presentation

Zoetis Inc. (ZTS) Q3 2024 Earnings Call Transcript

Top 50 High-Quality Dividend Growth Stocks - October 2024 Results

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zoetis (ZTS – Research Report), Verona Pharma (VRNA ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Zoetis ( ($ZTS) ) has released its Q3 earnings. Here is a breakdown of the information Zoetis presented to its investors. Zoetis Inc., a leading an...

Zoetis Reports Strong Q3 2024 Financial Results

AAPL

ALLE

AMAT

ATSG

BNTX

CTAS

DOCN

EDIT

ENTG

FAST

FRPT

GRMN

IART

JKHY

KLAC

LECO

LRCX

MKTX

MPWR

MSCI

MSFT

NSSC

NTES

ODFL

PAYX

POOL

QCOM

RACE

ROST

RVTY

SCHD

TGTX

TSCO

VRNA

Press Releases

Zoetis Announces Time Change for Second Quarter 2024 Financial Results Webcast and Conference Call

Zoetis Announces Authorization of Multi-Year $6 Billion Share Repurchase Program

Zoetis Announces Second Quarter 2024 Results

Small Cap

Opinion

Sustainable Agriculture: The Growing Need for Biotech Innovations in the World's Food Supplies

Zoetis to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Zoetis to Host Webcast and Conference Call on Third Quarter 2024 Financial Results

Zoetis and Danone Announce Strategic Partnership to Pioneer Sustainable Innovation in Dairy Farming Using the Power of Genetics

Zoetis Declares Fourth Quarter 2024 Dividend

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products

Zoetis Announces Third Quarter 2024 Results

BRFS

BVAXF

CSE:BIOV

CTVA

PAHC

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Zoetis

Actualités

Dernières nouvelles pour Zoetis (NYSE:ZTS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL